Literature DB >> 19174310

Administration of bone marrow stromal cells ameliorates experimental autoimmune myasthenia gravis by altering the balance of Th1/Th2/Th17/Treg cell subsets through the secretion of TGF-beta.

Qing-Fei Kong1, Bo Sun, Sha-Sha Bai, Dong-Xu Zhai, Guang-You Wang, Yu-Mei Liu, Shu-Juan Zhang, Rui Li, Wei Zhao, Yan-Yan Sun, Na Li, Qi Wang, Hai-Sheng Peng, Lian-Hong Jin, Hu-Lun Li.   

Abstract

Bone marrow stromal cells (BMSCs) are strong candidates for cell therapy against human autoimmune diseases. Intravenous administration of syngenic BMSCs to EAMG-model rats effectively ameliorated the disease, partially through a TGF-beta-dependent mechanism. The proliferative ability of T or B cells from EAMG rats was inhibited by BMSCs at proper cocultured ratios. And the imbalance of Th1, Th2, Th17 and Treg cell subsets accompanied with the development of EAMG was corrected by the administration of BMSCs. These results provide further insights into the pathogenesis of MG, EAMG, and other immune-mediated diseases, and support a potential role for BMSCs in their treatment.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19174310     DOI： 10.1016/j.jneuroim.2008.12.005

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN： 0165-5728            Impact factor:   3.478


  38 in total

1.  Neutralization of interleukin-9 ameliorates symptoms of experimental autoimmune myasthenia gravis in rats by decreasing effector T cells and altering humoral responses.

Authors:  Xiuhua Yao; Qingfei Kong; Xiaoli Xie; Jinghua Wang; Na Li; Yumei Liu; Bo Sun; Ying Li; Guangyou Wang; Wenjin Li; Siying Qu; Haijun Zhao; Dandan Wang; Xijun Liu; Yao Zhang; Lili Mu; Hulun Li
Journal:  Immunology       Date:  2014-11       Impact factor: 7.397

Review 2.  The bone marrow stroma in hematological neoplasms--a guilty bystander.

Authors:  Claudio Tripodo; Sabina Sangaletti; Pier P Piccaluga; Sonam Prakash; Giovanni Franco; Ivan Borrello; Attilio Orazi; Mario P Colombo; Stefano A Pileri
Journal:  Nat Rev Clin Oncol       Date:  2011-03-29       Impact factor: 66.675

Review 3.  Rejuvenation of mucosal immunosenescence by adipose tissue-derived mesenchymal stem cells.

Authors:  Akitoshi Tsuruhara; Kazuyoshi Aso; Daisuke Tokuhara; Junichiro Ohori; Masaki Kawabata; Yuichi Kurono; Jerry R McGhee; Kohtaro Fujihashi
Journal:  Int Immunol       Date:  2017-01-01       Impact factor: 4.823

4.  Mesenchymal Stem Cells Attenuate the Adverse Effects of Immunosuppressive Drugs on Distinct T Cell Subopulations.

Authors:  Michaela Hajkova; Barbora Hermankova; Eliska Javorkova; Pavla Bohacova; Alena Zajicova; Vladimir Holan; Magdalena Krulova
Journal:  Stem Cell Rev Rep       Date:  2017-02       Impact factor: 5.739

5.  Effects of transcutaneous acupoint electrical stimulation on the imbalance of Th1, Th2, Th17 and Treg cells following thoracotomy of patients with lung cancer.

Authors:  Huaxing Wu; Kun Wang; Guixian Li; Dexin Meng; Jiacheng Han; Guonian Wang; Y U Li
Journal:  Exp Ther Med       Date:  2015-12-04       Impact factor: 2.447

Review 6.  Molecular and Cellular Mechanisms Involved in Mesenchymal Stem Cell-Based Therapy of Inflammatory Bowel Diseases.

Authors:  Bojana Simovic Markovic; Tatjana Kanjevac; C Randall Harrell; Marina Gazdic; Crissy Fellabaum; Nebojsa Arsenijevic; Vladislav Volarevic
Journal:  Stem Cell Rev Rep       Date:  2018-04       Impact factor: 5.739

7.  Transcriptional repressor Blimp1 regulates follicular regulatory T-cell homeostasis and function.

Authors:  Guang Yang; Xiaosu Yang; Junmei Zhang; Guancheng Li; Dandan Zheng; Anjiao Peng; Jue Hu; Liqun Xu; Baifeng Yang; Huan Yang; Wenbin Zhou; Erdem Tuzun; Jing Li
Journal:  Immunology       Date:  2017-10-19       Impact factor: 7.397

Review 8.  Adipose-Derived Mesenchymal Stem Cells in Autoimmune Disorders: State of the Art and Perspectives for Systemic Sclerosis.

Authors:  Alexandre T J Maria; Marie Maumus; Alain Le Quellec; Christian Jorgensen; Danièle Noël; Philippe Guilpain
Journal:  Clin Rev Allergy Immunol       Date:  2017-04       Impact factor: 8.667

9.  Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells.

Authors:  Maria Manuela Rosado; Maria Ester Bernardo; Marco Scarsella; Antonella Conforti; Ezio Giorda; Simone Biagini; Simona Cascioli; Francesca Rossi; Isabella Guzzo; Marina Vivarelli; Luca Dello Strologo; Francesco Emma; Franco Locatelli; Rita Carsetti
Journal:  Stem Cells Dev       Date:  2015-01-01       Impact factor: 3.272

10.  Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy.

Authors:  P Cipriani; P Di Benedetto; V Liakouli; B Del Papa; M Di Padova; M Di Ianni; A Marrelli; E Alesse; R Giacomelli
Journal:  Clin Exp Immunol       Date:  2013-08       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.